View Older Stories View More Recent Stories
-
Nkarta (NKTX) Prices $240M Share and Warrant Offering at $10/sh
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
Form 4 BiomX Inc. For: Mar 15 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 3 BiomX Inc. For: Mar 15 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
-
Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
-
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
-
Ventyx Biosciences (VTYX) Prices 11.17M Share Offering at $8.95/sh
-
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
-
BiomX (PHGE) and Adaptive Phage Therapeutics to Merge, Enter $50M Financing
-
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
Endologix Appoints Mike Mathias as Chief Commercial Officer
-
Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study
-
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
-
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
-
MMI Raises $110 Million in Series C Financing
-
Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Engene (ENGN) Announces 20M Share Placement at $10/sh
-
enGene Announces Oversubscribed $200 Million Private Placement Financing
-
Pairwise Shares Updated Strategy to Deliver High-Impact Societal and Climate Benefits
-
Cohere Health Raises $50 Million in Equity to Meet Increased Demand for AI-Driven Transformation of Prior Authorization Process
-
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
-
Windtree Therapeutics (WINT) Wins $15M Contingent Liability To Deerfield Management Company
-
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
-
Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator
-
Windtree (WINT) Eliminates $15M Contingent Liability to Deerfield Management Company
-
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
-
Endologix Announces that Art Taylor Joins Board of Directors
-
Kura Oncology (KURA) Prices 1.38M Share Offering at $17.25/sh
-
Kura Oncology Announces Oversubscribed $150 Million Private Placement
-
CalciMedica (CALC) Announces Private Placement of up to Approximately $55 Million
-
CalciMedica Announces Private Placement of up to Approximately $55 Million
-
Edgewise Therapeutics (EWTX) Prices $240 Million Underwritten Offering of Common Stock
-
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
-
Advanced Medicine Partners Launches to Set New Standard for Manufacturing and Testing Advanced Medicines
-
Washington University and Deerfield Management Launch VeritaScience to Drive Drug Discovery
-
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
-
MMI and ab medica Partner to Expand Access to Symani® Surgical System
-
Endologix Announces that Scott Ward Joins Board of Directors
-
Solid Biosciences (SLDB) Enters $108.9M Private Placement
-
Solid Biosciences Announces $109 Million Private Placement
-
MMI to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery
-
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
-
Valneva Provides Updated 2023 Financial Guidance
-
Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through (TPT) Payment for the DETOUR™ System
-
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
